Episode Details

Summary

Sapna reveals her most used emoji is a heart (awww..... <3) and James just avoids the question. Neither has decided on their theme song as a wrestler which means they won't be quitting their day jobs anytime soon.

In this episode, James and Sapna discuss the injectable treatment SD101, its mechanism, efficacy in different patient populations, and the challenges faced in its development. They explore the significance of the study results of SD101 plus pembrolizumab, particularly in PD-1 naive and refractory patients, and the implications for future research and treatment strategies in melanoma.

Keywords

SD101, pembrolizumab, melanoma, immunotherapy, PD-1, toll-like receptor, cancer treatment, clinical trials, efficacy, safety

Takeaways

SD101 shows a high response rate in PD-1 naive patients.

The mechanism of SD101 involves toll-like receptor 9 agonism.

Safety and tolerability of SD101 were confirmed in the study.

Efficacy in PD-1 refractory patients is lower but shows potential.

The study included correlative analyses that revealed immune responses.

Manufacturing and development challenges have impacted SD101's progress.

Not all toll-like receptor agonists have the same effects.

The concept of 'turning cold tumors hot' is crucial in treatment.

Future studies are needed to explore SD101's full potential.

The development of SD101 has shifted focus to rare tumors.

Sound Bites

"High response rate in PD-1 naive patients."

"Turning cold tumors hot is a challenge."

"SD101 is safe and tolerable."

Chapters

00:00 Introduction and Quick Questions

03:44 Overview of the SD101 Trial

05:39 Efficacy in PD-1 Naive and PD-1 Refractory Patients

08:04 Efficacy in the Refractory Setting

11:17 Development and Future of SD101

13:59 Comparison with Other Toll-Like Receptor 9 Agonists

15:51 Summary and Conclusion